Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Chengpei,Zhu ^[1] ; Jingnan,Xue ^[1] ; Yunchao,Wang ^[1] ; Shanshan,Wang ^[1] ; Nan,Zhang ^[1] ; Yanyu,Wang ^[1] ; Longhao,Zhang ^[1] ; Xu,Yang ^[1] ; Junyu,Long ^[1] ; Xiaobo,Yang ^[1] ; Xinting,Sang ^[1] ; Haitao,Zhao ^[1]

作者单位： Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China. ^[1]

关键词 Gemox chemotherapy PD-1 inhibitor PD-L1 inhibitor advanced biliary tract cancer lenvatinib

主题词人类(Humans);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);胆管肿瘤(Bile Duct Neoplasms);胆管, 肝内(Bile Ducts, Intrahepatic);胆道肿瘤(Biliary Tract Neoplasms);脱氧胞苷(Deoxycytidine);回顾性研究(Retrospective Studies)

DOI 10.3389/fimmu.2023.1109292

PMID 36742297

发布时间 2023-03-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交